MARKET WIREReuters • 3h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
Why PPCB Stock Traded Steady Today — RQD Quant Desk Flash
$2.11 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $2.11
Propanc Biopharma Inc. (PPCB) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $2.2M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $2.11 (-0.19%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-10% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PPCB)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (36/100 Composite)
🔍 WHY PPCB SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (22% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$4.86-29.6% Next Q
44
Q2 (-2Q)Grade D$3.42-18.1% Next Q
41
Q3 (-1Q)Grade E$2.80-24.6% Next Q
39
CurrentGrade D-$2.11-8.3% Hist 90D α
36
Trajectory: D (44) → D- (36)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a PPCB Turnaround Squeeze
While PPCB currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.72) and Max Pain ($2.22) forces dealer call-delta covering toward $330.75.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $PPCB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PPCB Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why PPCB Stock Traded Steady Today — RQD Quant Desk Flash
Propanc Biopharma Inc. (PPCB) slipped 0.00% to $2.11, trading at 2% of its 52-week range ($1.79 – $315). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($1.79 – $315) with RSI-14 at 21.2 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $2.11 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live PPCB Headlines & Catalysts
MARKET WIRECNBC • 5h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 5h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 6h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 7h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 8h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 9h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 9h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PPCB)
- ✓Walkthrough of PPCB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
PPCB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -91.69%▼ SUPPORT BREAKDOWN
2026-10-30O $1.91H $2.13L $1.79C $2.11VOL 64.6K
RES: $18.72SUP: $2.50SMA50: $6.72SMA200: $23.44
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
PPCB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on PPCB today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for PPCB. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PPCB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PPCB)
Health Care Rank #804 of 1016
⚔️ ELAB vs PPCB Full Matrix →
1. Head-to-Head Health Care Peer Comparison (PPCB vs. ELAB, REVB, BDRX, SILO)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Propanc Biopharma Inc. (PPCB) ranks #804 by composite RQD confidence (36/100, grade D-) and #994 by equity capitalization ($2.2M). Within this direct 5-issuer industry benchmark cohort, PPCB leads on earnings valuation at N/A trailing P/E, while PPCB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. REVB currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with PPCB at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PPCB
ACTIVE
Propanc Biopharma Inc. | D- | 36/100 | — | — | -35.0% | 0.00% | $2.2M | Benchmark Subject |
| ELAB PMGC Holdings Inc. | D- | 36/100 | — | 31.4% | -35.0% | +2.72% | $2.1M | /elab-vs-ppcb → |
| REVB Revelation Biosciences Inc. | D | 49/100 | — | — | -35.0% | +0.81% | $2.1M | /revb-vs-ppcb → |
| BDRX Biodexa Pharmaceuticals plc American Depositary Shs | D | 48/100 | — | — | — | -5.80% | $2.0M | /bdrx-vs-ppcb → |
| SILO Silo Pharma Inc. | E | 19/100 | — | 38.6% | -35.0% | -6.72% | $2.4M | /silo-vs-ppcb → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001517681In its most recent audited fiscal period (FY2025, filed 2025-06-30), Propanc Biopharma Inc. (PPCB) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$58.9M, operating cash flow of -$405.2K, and free cash flow of -$405.2K (+56.7% YoY). On the balance sheet, PPCB closed FY2025 with $15.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-06-30 | $0 | -$58.9M | -$405.2K | -$405.2K | $15.1M | — |
| FY2024 (FY) | 2024-06-30 | $0 | -$1.8M | -$935.1K | -$935.1K | $78.5K | — |
| FY2023 (FY) | 2023-06-30 | $0 | -$2.7M | -$1.1M | -$1.1M | — | — |
3. PPCB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs PPCB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Propanc Biopharma Inc. (NASDAQ: PPCB) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $2.11 (0.00% 1D, market cap $2.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PPCB ranks #804 in composite RQD confidence.
How does PPCB compare to ELAB and REVB in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PPCB carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ELAB (PMGC Holdings Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $2.1M) and REVB (Revelation Biosciences Inc.) posts a D grade (49/100 RQD, P/E N/A, ROIC -35.0%, cap $2.1M). Among the 5-stock peer group, PPCB leads on earnings multiple (N/A) while PPCB leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for PPCB?
Per PPCB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001517681), Propanc Biopharma Inc. generated $0 in revenue, -$58.9M in net income, and -$405.2K in free cash flow against $15.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is PPCB trading relative to its 50-day, 200-day, and 52-week technical levels?
PPCB last traded at $2.11 (0.00% on volume of 30,628 shares), positioning the stock -68.60% below its 50-day simple moving average ($6.72) and -91.00% below its 200-day simple moving average ($23.44). Across its 52-week range of $1.79 to $315.00, PPCB sits at the 0.1% percentile with a 14-day RSI of 21.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.85 to $2.37).
PPCB Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is PPCB stock moving today?
Why PPCB Stock Traded Steady Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.